Bilateral Adrenal Incidentalomas
DOI:
https://doi.org/10.12970/2310-9971.2020.08.04Keywords:
Bilateral, adrenal, incidentaloma, pheochromocytoma, metastases.Abstract
Introduction: Bilateral adrenal incidentaloma presents a unique diagnostic challenge. Besides the risk of hormonal hypersecretion, bilateral adrenal lesion carries an additional risk of being metastatic from another primary carcinoma or part of a genetic syndrome. The discovery of a bilateral adrenal incidentaloma requires special attention and a broad diagnostic approach. This study is focused on the clinical, biological, etiological, therapeutic and progressive characteristics of bilateral adrenal incidentalomas. Patients and Methods: Descriptive retrospective study of 9 patients with bilateral adrenal incidentaloma from 2015 to 2020. Results: The mean age was 45±20 years with a predominance of male 77% (n=7). Adrenal masses were discovered during abdominal computed tomography in 77% of cases, abdominal ultrasound in 22% of cases. The reason for performing the radiological assessment was abdominal pain in 55% of patients (n=5), exploration of the hypertension in 33% (n=3), other causes were found in 11% of cases. Hormonal and biological exploration found a bilateral pheochromocytoma in 77%. The treatment was bilateral adrenalectomy in 44%, unilateral in 33%. Other treatments were offered for the rest of patient. Conclusion: The fortuitous radiological discovery of a bilateral adrenal incidentaloma should lead to additional explorations to clarify its nature, which will guide the treatment.References
[1] Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. European Journal of Endocrinology 2011; 164(6): 851-870. https://doi.org/10.1530/EJE-10-1147
[2] Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation 2006; 29(4): 298-302. https://doi.org/10.1007/BF03344099
[3] Vassiliadi DA, Tsagarakis S, Stylianos. Endocrine incidentalomas—challenges imposed by incidentally discovered lesions. Nature Reviews Endocrinology 2011; 7(11): 668. https://doi.org/10.1038/nrendo.2011.92
[4] Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. American Journal of Roentgenology 2008; 190(5): 1163-1168. https://doi.org/10.2214/AJR.07.2799
[5] Vassiliadi DA, Ntali G, Vicha E, Tsagarakis S. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clinical Endocrinology 2011; 74(4): 438-444. https://doi.org/10.1111/j.1365-2265.2010.03963.x
[6] Hedeland H, Östberg G, Hökfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Medica Scandinavica 1968; 184(1‐6): 211-214. https://doi.org/10.1111/j.0954-6820.1968.tb02445.x
[7] Zeiger M, Thompson G, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009; 15(Supplement 1): 1-20. https://doi.org/10.4158/EP.15.S1.1
[8] Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008; 249(3): 756-775. https://doi.org/10.1148/radiol.2493070976
[9] Young Jr WF. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinology and metabolism clinics of North America 2000; 29(1): 159-185. https://doi.org/10.1016/S0889-8529(05)70122-5
[10] Young Jr WF. The incidentally discovered adrenal mass. New England Journal of Medicine 2007; 356(6): 601-610. https://doi.org/10.1056/NEJMcp065470
[11] Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical outcomes in adrenal incidentaloma: experience from one center. Endocrine Practice 2015; 21(8): 870-877. https://doi.org/10.4158/EP15618.OR
[12] Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. The Journal of Clinical Endocrinology & Metabolism 2000; 85(2): 637-644. https://doi.org/10.1210/jc.85.2.637
[13] Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Iistrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991; 110(6): 1014-1021.
[14] Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. The Journal of Clinical Endocrinology & Metabolism 1999; 84(2): 520-526. https://doi.org/10.1210/jc.84.2.520
[15] Lamblin A, Pigny P, Tex G, et al. Paragangliomes: profil clinique et sécrétoire: À propos de 39 cas. In: Annales de chirurgie. Elsevier Masson 2005; pp. 157-161. https://doi.org/10.1016/j.anchir.2004.12.001
[16] Brunaud L, Ayav A, Bresler L, Klein M, Boissel P. Les problèmes diagnostiques du phéochromocytome. In: Annales de chirurgie 2005; pp. 267-272. https://doi.org/10.1016/j.anchir.2005.02.008
[17] Raby L. Bilateral Pheochromocytomas: Incidental Finding in a Trauma Patient. Journal of Emergency Nursing 2011; 37(5): 512-514. https://doi.org/10.1016/j.jen.2011.04.018
[18] Mirallié E, Cariou B, Kraeber-Bodéré F. Phéochromocytomes bilatéraux. Génétique et traitement. In: Annales de chirurgie 2005; pp. 273-276. https://doi.org/10.1016/j.anchir.2005.02.009
[19] Plouin PF, Gimenez-Roqueplo AP, Alanore ALB, Salenave S, Duclos JM. Progrès récents dans le diagnostic, l’évaluation pronostique et le traitement des phéochromocytomes. La Revue de Médecine Interne 2000; 21(12): 1075-1085. https://doi.org/10.1016/S0248-8663(00)00268-X
[20] Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology & Metabolism 2007; 3(2): 92-102. https://doi.org/10.1038/ncpendmet0396
[21] Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical outcomes in adrenal incidentaloma: experience from one center. Endocrine Practice 2015; 21(8): 870-877. https://doi.org/10.4158/EP15618.OR
[22] Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? European Journal of Endocrinology 2009; 161(4): 513. https://doi.org/10.1530/EJE-09-0234
[23] Mantero F, Terzolo M, Arnaldi G, et al. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000; 85(2): 637-644. https://doi.org/10.1210/jc.85.2.637
[24] Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism 2002; 87(3): 998-1003. https://doi.org/10.1210/jcem.87.3.8277
[25] Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. The Journal of Clinical Endocrinology & Metabolism 2011; 96(5): 1223-1236. https://doi.org/10.1210/jc.2010-2722
[26] Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 2016; 175(2): G1-G34. https://doi.org/10.1530/EJE-16-0467
[27] Castinetti F, Taieb D, Henry JF, et al. Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. European Journal of Endocrinology 2016; 174(1): R9-R18. https://doi.org/10.1530/EJE-15-0549
